325 related articles for article (PubMed ID: 14660630)
1. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
[TBL] [Abstract][Full Text] [Related]
2. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer.
Liao Y; Mu G; Zhang L; Zhou W; Zhang J; Yu H
Dig Dis Sci; 2013 Dec; 58(12):3524-33. PubMed ID: 24061591
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.
Sako A; Kitayama J; Shida D; Suzuki R; Sakai T; Ohta H; Nagawa H
J Surg Res; 2006 Jan; 130(1):94-101. PubMed ID: 16171822
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
6. LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.
Chen M; Towers LN; O'Connor KL
Am J Physiol Cell Physiol; 2007 May; 292(5):C1927-33. PubMed ID: 17496233
[TBL] [Abstract][Full Text] [Related]
7. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
Komachi M; Sato K; Tobo M; Mogi C; Yamada T; Ohta H; Tomura H; Kimura T; Im DS; Yanagida K; Ishii S; Takeyoshi I; Okajima F
Cancer Sci; 2012 Jun; 103(6):1099-104. PubMed ID: 22348348
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid signaling via LPA
Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
[TBL] [Abstract][Full Text] [Related]
9. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
Miyabe Y; Miyabe C; Iwai Y; Yokoyama W; Sekine C; Sugimoto K; Harigai M; Miyasaka M; Miyasaka N; Nanki T
Arthritis Res Ther; 2014 Oct; 16(5):461. PubMed ID: 25273676
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
Yu S; Murph MM; Lu Y; Liu S; Hall HS; Liu J; Stephens C; Fang X; Mills GB
J Natl Cancer Inst; 2008 Nov; 100(22):1630-42. PubMed ID: 19001604
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells.
Masiello LM; Fotos JS; Galileo DS; Karin NJ
Bone; 2006 Jul; 39(1):72-82. PubMed ID: 16487757
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2.
Yamada T; Yano S; Ogino H; Ikuta K; Kakiuchi S; Hanibuchi M; Kanematsu T; Taniguchi T; Sekido Y; Sone S
Cancer Sci; 2008 Aug; 99(8):1603-10. PubMed ID: 18754873
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer.
Shida D; Watanabe T; Aoki J; Hama K; Kitayama J; Sonoda H; Kishi Y; Yamaguchi H; Sasaki S; Sako A; Konishi T; Arai H; Nagawa H
Lab Invest; 2004 Oct; 84(10):1352-62. PubMed ID: 15220934
[TBL] [Abstract][Full Text] [Related]
14. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1.
Shida D; Kitayama J; Yamaguchi H; Okaji Y; Tsuno NH; Watanabe T; Takuwa Y; Nagawa H
Cancer Res; 2003 Apr; 63(7):1706-11. PubMed ID: 12670925
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
[TBL] [Abstract][Full Text] [Related]
17. Dioleoyl phosphatidic acid increases intracellular Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts.
Chang YJ; Kim YL; Lee YK; Sacket SJ; Kim K; Kim HL; Han M; Bae YS; Okajima F; Im DS
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):268-76. PubMed ID: 17499746
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid stimulates prostaglandin E2 production in cultured stromal endometrial cells through LPA1 receptor.
Woclawek-Potocka I; Kondraciuk K; Skarzynski DJ
Exp Biol Med (Maywood); 2009 Aug; 234(8):986-93. PubMed ID: 19491366
[TBL] [Abstract][Full Text] [Related]
19. Gintonin, newly identified compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affinity.
Hwang SH; Shin TJ; Choi SH; Cho HJ; Lee BH; Pyo MK; Lee JH; Kang J; Kim HJ; Park CW; Shin HC; Nah SY
Mol Cells; 2012 Feb; 33(2):151-62. PubMed ID: 22286231
[TBL] [Abstract][Full Text] [Related]
20. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
